Phosphorylation of 3′-azidothymidine in maternal and fetal peripheral blood mononuclear cells during gestation and at term

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 5, 2003, Pages 477-481

  Agbaria, Riad ^a   Manor, Esther ^b   Barak, Jacob ^b   Balzarini, Jan ^c  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Amniocytes; AZT; HIV; Maternal fetal HIV transmission; PBMCs; Phosphorylation

Indexed keywords

DRUG METABOLITE; UNCLASSIFIED DRUG; ZIDOVUDINE; ZIDOVUDINE 5' TRIPHOSPHATE; ZIDOVUDINE PHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AMNION CELL; ANION EXCHANGE; ARTICLE; BLOOD SAMPLING; CELL ISOLATION; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; FETUS; FETUS BLOOD; GESTATIONAL AGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATERNAL BLOOD; MONONUCLEAR CELL; NORMAL HUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; SERODIAGNOSIS; UMBILICAL CORD BLOOD; VERTICAL TRANSMISSION; AMNION; CYTOLOGY; FETOMATERNAL TRANSFUSION; METABOLISM; PREGNANCY; SECOND TRIMESTER PREGNANCY;

AMNION; ANTI-HIV AGENTS; FEMALE; FETAL BLOOD; HUMANS; LEUKOCYTES, MONONUCLEAR; MATERNAL-FETAL EXCHANGE; PHOSPHORYLATION; PREGNANCY; PREGNANCY TRIMESTER, SECOND; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 0037446447     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200304150-00002     Document Type: Article

References (22)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
2. Zimmerman TP, Mahony WB, Prus KL. 3′-Azido-3′-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J Biol Chem. 1987;262:5748-5754.
3. Cooney DA, Ahluwalia G, Mitsuya H, et al. Initial studies on the cellular pharmacology of 2′,3′-dideoxyadenosine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol. 1987;36:1765-1768.
4. Furman PA, Fyfe JA, St Clair MH, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA. 1986;83:8333-8337.
5. Cheng YC, Dutschman GE, Bastow KF, et al. Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs. Biol Chem. 1987; 262:2187-2189.
6. Vrang L, Bazin H, Remaud G, et al. Inhibition of the reverse transcriptase from HIV by 3′-azido-3′-deoxythymidine triphosphate and its threo analogue. Antiviral Res. 1987;7:139-149.
7. Mitsuya H, Matsukura M, Broder S. Modern concepts and chemotherapeutic challenges. In: Broder S, ed. AIDS. New York: Marcel Dekker, 1987:303.
8. Lopez-Anaya A, Unadkat JD, Schumann LA, et al. Pharmacokinetics of zidovudine (azidothymidine). I. Transplacental transfer. J Acquir Immune Defic Syndr Hum Retrovirol. 1990;3:959-9564.
9. Liebes L, Mendoza S, Wilson D, et al. Transfer of zidovudine (AZT) by human placenta. J Infect Dis. 1990;161:203-207.
10. Schenker S, Johnson RF, King TS, et al. Azidothymidine (zidovudine) transport by the human placenta. Am J Med Sci. 1990;299:16-20.
11. Pons JC, Taburet AM, Singlas E, et al. Placental passage of azathiothymidine (AZT) during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Eur J Obstet Gynecol Reprod Biol. 1991;40:229-231.
12. Watts DH, Brown ZA, Tartaglione T, et al. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis. 1991;163:226-232.
13. Balzarini J, Naesens L, Aquaro S, et al. Intracellular metabolism of CycloSaligenyl 3′-azido-2′, 3′-dideoxythymidine monophosphate, a prodrug of 3′-azido-2′, 3′-dideoxythymidine (zidovudine). Mol Pharmacol. 1999;56:1354-1361.
14. Rodman JH, Flynn PM, Robbins B, et al. Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants. J Infect Dis. 1999;180:1844-1850.
15. Qian M, Bui T, Ho RJ, et al. Metabolism of 3′-azido-3′-deoxythymidine (AZT) in human placental trophoblasts and Hofbauer cells. Biochem Pharmacol. 1994;48:383-389.
16. Vazquez-Padua MA, Starnes MC, Cheng YC. Incorporation of 3′-azido-3″-deoxythymidine into cellular DNA and its removal in a human leukemic cell line. Cancer Commun. 1990;2:55-62.
17. Bui T, Bark D, Perkins M, et al. Effect of zidovudine on human placental trophoblast and Hofbauer cell functions. J Acquir Immune Defic Syndr Hum Retrovirol. 1993;6:120-126.
18. Antiretroviral pregnancy registry. PharmaResearch Corp., Wilmington, NC. January 1989-July 1997.
19. Sperling RS, Shapiro DE, McSherry GD, et al. Safety of the maternal-infant zidovudine regimen used in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS. 1998;12:1805-1813.
20. White A, Eldridge R, Andrews E. Birth outcomes following zidovudine exposure in pregnant women: the Antiretroviral Pregnancy Registry. Acta Paediatr Suppl. 1997;421:86-88.
21. Gao WY, Agbaria R, Driscoll JS, et al. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem. 1994;269:12633-12638.
22. Tornevik Y, Jacobsson B, Britton S, et al. Intracellular metabolism of 3′-azidothymidine in isolated human peripheral blood mononuclear cells. AIDS Res Hum Retroviruses. 1991;7:751-759.